ProMetic announces scale-up of prion removal resin in plasma product for biopharmace...(l 2002 by The American Red Cross and Pro...)

Date:1/23/2008

l 2002 by The American Red Cross and ProMetic Life Sciences Inc., and allows for the exchange of technology and knowledge between the two organizations. PRDT's main goal is to develop products and devices to remove and detect different pathogens from biological sources. This research augments work that ProMetic, the American Red Cross and PRDT's scientific founders have been conducting independently for many years.

Forward Looking Statements

This press release contains forward-looking statements about ProMetic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, ProMetic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of ProMetic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations on page 21 of ProMetic's Annual Information Form for the year ended December 31, 2006, under the heading "Risk Factors". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless requi
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. Vapotherm(R) Announces Validation of U.S. Patent
3. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
4. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
5. Elekta Announces First Two Clinical Sites Using VMAT Cancer Treatment Capability
6. Amarin Provides Business Update and Announces Implementation of Reverse Stock Split
7. Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories
8. Peptimmune Announces First Close of Series D Private Financing
9. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
10. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
11. Vasogen Announces 2007 Year-End Results